(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase I drugs for Cervical Intraepithelial Neoplasia (CIN) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Lopinavir + ritonavir)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Lopinavir + ritonavir) overview
Lopinavir in combination with ritonavir (R-131) is under development for the treatment of genital warts (condylomata acuminata) and cervical intraepithelial neoplasia. It is administered through vaginal route as soft gel capsule.
It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus.
Douglas Pharmaceuticals overview
Douglas Pharmaceuticals (Douglas) carries out the development and manufacture of nutraceutical and health products. The company offers consumer, prescription and automation products. Its investigational medicinal products comprise R-107, R-131 and R-147. Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services. It markets its consumer products under various brands which include 3M Futuro, Altrix Range, Avene, Bio Oil, Puria and Resolve, among others. Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US. Douglas is headquartered in Auckland City, Auckland, New Zealand.
For a complete picture of (Lopinavir + ritonavir)’s drug-specific PTSR and LoA scores, buy the report here.